Literature DB >> 3518992

Genetics of drug transformation.

W Kalow.   

Abstract

Biotransformations of drugs are controlled or strongly affected by genetic factors. During the past few years several genetic deficiencies of drug-metabolizing reactions catalyzed by members of the family of cytochrome P-450 were observed. Choice of the appropriate drug to study and attention to urinary metabolites have been the essential ingredients for the recent discovery of genetic deficiencies of drug metabolism in man which include recessive deficiency of debrisoquine/sparteine metabolism and of mephenytoin metabolism. The clinical significance of these defects is discussed. Ethanol after metabolism to acetaldehyde is further metabolized to acetic acid by aldehyde dehydrogenase. Numerous isozymes of aldehyde dehydrogenase exist, one of which possesses a high affinity for acetaldehyde. Approximately 40% of the Oriental population lack this high affinity isozyme so that in these individuals who may have symptoms of flushing and other unpleasant effects the acetaldehyde formed is destroyed only at high plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3518992     DOI: 10.1016/s0009-9120(86)80052-2

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  13 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot.

Authors:  L Endrenyi; M Patel
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

4.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

6.  Population pharmacokinetics of omeprazole in a random Iranian population.

Authors:  Shahran Ala; Fatemeh Zanad; Mohammad Reza Shiran
Journal:  Caspian J Intern Med       Date:  2013

Review 7.  Genetic factors in neurotoxicology and neuropharmacology: a critical evaluation of the use of genetics as a research tool.

Authors:  M F Festing
Journal:  Experientia       Date:  1991-10-15

8.  Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats.

Authors:  S A Wrighton; P E Thomas; P Willis; S L Maines; P B Watkins; W Levin; P S Guzelian
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 9.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  A pharmacokinetic study of trifluoperazine in two ethnic populations.

Authors:  K K Midha; E M Hawes; J W Hubbard; E D Korchinski; G McKay
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.